
Releases
Embecta Faces Securities Class Action Over Insulin Needle Business
Investors who suffered heavy losses after Embecta Corp. shares plummeted 57.8% in a single day are now turning to the courts. A class action lawsuit filed in New Jersey alleges the company misled shareholders about the commercial stability of its insulin pen needle business throughout late 2025 and early 2026.



























